Doctor of Osteopathy Program year 2020 Reported 2019–2020 Source: CMS Open Payments, 2026 publication

Christopher Lucas

Internal Medicine Paoli, PA Doctor of Osteopathy

NPI 1538136387 CMS profile 160517

255 W Lancaster Ave Mob 2 Ste 120, 120 Paoli Mob II, Paoli, PA 19301

Open in the dashboard

General payments

$592

36 records reported · program years 2019–2020

Research payments

$0

Paid to them · None reported · program years 2019–2020

Ownership & investment interest

$0

None reported

Through program year 2020, Christopher Lucas of Paoli, PA is reported in the CMS Open Payments database as having received $592 across 36 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 62nd percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

2 rows
Year Kind Relative to this record's peak year Amount Records
2020 General $169 10
2019 General $423 26

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Christopher Lucas
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Christopher Lucas were reported at $0. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Christopher Lucas Internal Medicine median Middle half National median
2019 $423 $159 $48–$570 $163
2020 $169 $119 $33–$402 $114
2021 $0 $135 $37–$521 $132
2022 $0 $141 $42–$496 $149
2023 $0 $149 $45–$519 $160
2024 $0 $154 $47–$537 $164
2025 $0 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2020
  1. AstraZeneca Pharmaceuticals LP $217 12 payments
  2. Amgen Inc. $115 7 payments
  3. Kowa Pharmaceuticals America, Inc. $82 6 payments
  4. Novo Nordisk Inc $50 3 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $45 3 payments
  6. IBSA Pharma Inc. $34 2 payments
  7. Pfizer Inc. $18 1 payment
  8. Janssen Pharmaceuticals, Inc $17 1 payment
  9. Ironwood Pharmaceuticals, Inc $14 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2020
  1. Food and Beverage $586 35 payments
  2. Education $6 1 payment
Products named General payments · program years 2019–2020
  1. FARXIGA $179 11 payments
  2. Prolia $115 7 payments
  3. Livalo $82 6 payments
  4. Bystolic $69 5 payments
  5. EVENITY $65 4 payments
  6. SYMBICORT $37 1 payment
  7. Tirosint $34 2 payments
  8. Ozempic $34 2 payments
  9. Repatha $33 2 payments
  10. TRADJENTA $31 2 payments
  11. Other $201 13 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 88 drugs

Part D claims

3,762

Median for Internal Medicine: 777

Drug cost

$368,433

Median for Internal Medicine: $73,373

Branded share of claims

22.9%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 100 $117,441
Eliquis Apixaban Brand 62 $71,751
Ozempic Semaglutide Brand 44 $42,721
Xarelto Rivaroxaban Brand 16 $25,863
Januvia Sitagliptin Phosphate Brand 11 $15,528
Xanax Alprazolam Brand 16 $12,619
Crestor Rosuvastatin Calcium Brand 12 $9,019
Synthroid Levothyroxine Sodium Brand 55 $7,424
Praluent Pen Alirocumab Brand 13 $6,114
Breo Ellipta Fluticasone/Vilanterol Brand 14 $5,530

The 10 drugs with the highest cost, of 88 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 32 billing codes

Paid by Medicare

$108,065

Of which drugs: $13,055

Medicare patients

242

Average age 77

Services billed

1,487

107 women, 135 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 65%
Arthritis 45%
Ischemic heart disease 35%
Diabetes 22%
Atrial fibrillation 19%
Chronic kidney disease 19%
Cancer 19%
Osteoporosis 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 114 115 $9,370
Pcv20 vaccine im 90677 Office 11 11 $3,195

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

36 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2020

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record